Ruxandra Sîrbulescu heads up the VIC team admitted to IDEA2 Global 2017

Ruxandra Sîrbulescu heads up the VIC team admitted to IDEA2 Global 2017

MIT linQ, an international biomedical technology innovation consortium based at the Massachusetts Institute of Technology’s Institute for Medical Engineering and Sciences (MIT IMES), announced the 15 teams admitted to IDEA2 Global 2017. The 7-month program provides intensive innovation method training, collaborative project development, and team-specific mentoring and expertise to help teams move novel health technology ideas toward real-world application.

Proposals to IDEA2 Global were invited from anywhere in the world, and many were prequalified by the program’s partners. These partners, other organizations dedicated to fostering biomedical technology innovation, include Fundación para la Innovación y la Prospectiva en Salud en España (FIPSE, a Spain-based non-profit dedicated to advancing new healthcare technologies), the MIT Institute for Medical Engineering and Science (IMES), the Medicine Innovation Program at Massachusetts General Hospital, PDS (a US-based IT services and innovation company), and MIT Hacking Medicine.

The teams will meet at MIT in June for an initial workshop to sharpen the focus on the medical need they intend to address. They will then be matched with project mentors and subject and technology experts to help them develop their project over the summer. In October, the teams will meet again in a workshop to refine their project definition. Finally, in December they will gather to make their final pitches to a panel of judges, who will name the best projects.


Ruxandra’s team is researching: B cell immunotherapy for central nervous system injury

We propose to develop a novel cell-based immunotherapy for the acute and chronic treatment of central nervous system injuries. Based on preliminary data, our proposed cell therapy is expected to have multiple, pleiotropic effects in limiting inflammation after injury and promoting a permissive environment for neuroregeneration. Moreover, because of the easily accessible nature of the target cells – which can be isolated from peripheral blood – an autologous, minimally-invasive treatment will be relatively straightforward to translate into a clinical setting.

Team: Ruxandra F. Sîrbulescu, Ph.D., Ann E. Sluder, Ph.D., Timothy Brauns, MBA


A full list of the teams admitted can be seen here: